134 1. Aspetti Generali Ringraziamenti Un ringraziamento speciale ai Centri GITMO che hanno partecipato al lavoro retrospettivo GITMO Allo-Eld (Reggio Calabria, Udine, Torino “Città della Salute”, Milano Niguarda, Milano Humanitas, Pavia, Orbassano, Pescara, Monza, Ancona, Roma Università Cattolica, Bolzano, Firenze, Taranto, Piacenza, Milano Università Statale, Cagliari, Ascoli Piceno, Modena, Roma La Sapienza, Tricase, Mestre, Bari, Vicenza, Roma San Camillo, Salerno, Genova, Bergamo, Milano San Raffaele, Bologna) Bibliografia [1] Bair SM, Brandstadter JD, Ayers EC, Stadtmauer EA. Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer. 2020;126(9):1837–1855 [2] https://www.gitmo.it/index.php/report-trapianti-annuali [3] https://www.istat.it [4] Magliano G, Bacigalupo A. Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the Elderly: Review of Literature and New Perspectives. Mediterr J Hematol Infect Dis. 2020;12:(1) e2020081 [5] Varadarajan I, Ballen KK. What have we learned from transplanting older patients? Best Pract Res Clin Haematol. 2019;32(4):101–110 [6] Sorror ML, Maris MB, Storb B, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106 (8):2912–2919 [7] Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, Ho VT, Horowitz MM, Pasquini MC. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015;21(8):1479-87 [8] Vaughn JE, Storer BE, Armand P, Raimondi R, Gibson C, Rambaldi A et al. Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. Biol Blood Marrow Transplant 2015; 21(8): 1418–1424 [9] Wais V, Bunjes D, Kuchenbauer F, Sorror ML. Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes. Expert Rev Hematol. 2018 Oct;11(10):805-816 [10] Polverelli N, Tura P, Battipaglia G, Malagola M, Bernardi S, Gandolfi L, et al. Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A FrenchItalian 10-year experience on 228 patients. Bone Marrow Transplant. 2020;55(12):2224–2233 [11] Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug;99(8):1373-9 [12] Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B et al. GITMO registry study on allogeneic transplantationin patients aged ≥ 60 years from 2000 to 2017: improvements and criticisms. Transpl and Cell Ther 2022; 28:96e1-96e11 [13] Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versusHost Disease. N Engl J Med. 2016;374(1):43–53 [14] Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157–e167 [15] Bonifazi F, Rubio MT, Bacigalupo A, Boelens JJ, Finke J, Greinix H, et al. Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplant. 2020;55(6):1093–1102 [16] Polverelli N, Malagola M, Turra A, Skert C, Perucca S, Chiarini M, et al. Comparative study on ATG- thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years. Leuk Lymphoma. 2018;59(11):2700–2705 [17] Williams L, Cirrone F, Cole K, Abdul-Hay M, Luznik L, AS Al-Homsi. Posttransplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. Front Immunol. 2020;11:636. [18] Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344–353. [19] Weisdorf DJ. Reduced-intensity versus myeloablative allogeneic transplantation. Hematol Oncol Stem Cell Ther. 2017;10(4):321– 326 [20] Ragon BK. The Art of Transplantation: Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019;25(3):e71–e72 [21] Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, et al. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020;135(6):449–452 [22] Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, et al. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biol Blood Marrow Transplant. 2018;24(8):1733–1740. [23] Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, et al. Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome following allogeneic hematopoietic stem cell transplant - a systematic review and meta-analysis. Transplant Cell Ther. 2021;19:S2666–S6367 [24] Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, et al. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leuk Lymphoma. 2021;3:1–8 [25] Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99 (8):1373–1379 [26] Lin RJ, Elko TA, Devlin SM, Shahrokni A, Jakubowski AA, Dahi PB, et al. Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. Bone Marrow Transplant. 2020;55(1):157–164 [27] Olin RL, Fretham C, Pasquini MC, Arora M, Bhatt VR, Derman B, et al. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020;4 (12):2810–2820 [28] Cardoso AL, Fernandes A, Aguilar-Pimentel JA, de Angelis MH, Guedes JR, Brito MA, et al. Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases. Ageing Res Rev. 2018;47:214–277 [29] Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131(25):2846–2855
RkJQdWJsaXNoZXIy ODUzNzk5